Objective
The SHIELD project seeks to revolutionise early detection of pancreatic cancer, focusing on individuals with high heritable genetic risk. Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 10%, primarily due to late-stage diagnosis. Consequently, 85% of PDAC cases are identified too late for curative treatment. However, early detection can significantly improve outcomes, increasing the survival rate to 42% with surgical intervention. There is a pressing need for better early detection methods, especially for those with familial or genetic predispositions. The only FDA-approved biomarker, CA19-9, is limited to monitoring treatment response due to its lack of sensitivity and specificity, while imaging methods ofter fail to detect early-stage cancers and cause a strain to the healthcare system due to their cost and limited availability. SHIELD aims to validate a new blood-based diagnostic test designed for early PDAC detection in high-risk individuals and pilot an early detection programme in Greece, Slovenia and Lithuania. Developed by partner Reccan, this test uses a 5-plex multiple immunoassay to analyze protein readouts and provides a probability score for pancreatic cancer. Initial studies with over 450 samples showed excellent performance with >91% sensitivity and >96% specificity. The project will validate the test's clinical performance in a prospective multi-center study across seven EU countries, targeting individuals with familial or genetic predispositions. It will also identify new protein biomarkers for other high-risk indications, such as new-onset diabetes (NOD). Collaboration with national screening authorities will help integrate this test into existing programs, and partnerships with patient organizations will enhance recruitment. SHIELD envisions transforming pancreatic cancer diagnostics by increasing the 5-year survival rate to 30% by 2035 in Europe. This action is part of the Cancer Mission cluster of projects on “Prevention & early detection (early detection heritable cancers)
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciencesclinical medicineoncologyprostate cancer
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicineoncologypancreatic cancer
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
Call for proposal
(opens in new window) HORIZON-MISS-2024-CANCER-01
See other projects for this callFunding Scheme
HORIZON-IA - HORIZON Innovation ActionsCoordinator
2000 Maribor
Slovenia
See on map
Participants (25)
166 75 GLYFADA
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
00179 Roma
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2000 Maribor
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
223 81 Lund
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
See on map
106 80 ATHINA
See on map
176 71 Athina
See on map
22100 Lund
See on map
2417 NICOSIA
See on map
2371 AGIOS DOMETIOS
See on map
28015 Madrid
See on map
106 82 ATHINA
See on map
7100 Vejle
See on map
1253 Luxembourg
See on map
10561 Athina
See on map
223 81 Lund
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4000 Liege
See on map
01513 Vilnius
See on map
85579 Neubiberg
See on map
181 21 Lidingö
See on map
105 51 ATHINA
See on map
175 63 ATHENS
See on map
115 27 ATHENS
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
YO31 0AA York
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
177 78 Athens
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (1)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
8600 Dubendorf
See on map